{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Paules CI"],"funding":["NHLBI NIH HHS","National Institutes of Health","NIH HHS"],"pagination":["67"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11734232"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["25(1)"],"pubmed_abstract":["<h4>Background</h4>Low blood absolute lymphocyte count (ALC) may predict severe COVID-19 outcomes. Knowledge gaps remain regarding the relationship of ALC trajectory with clinical outcomes and factors associated with lymphopenia.<h4>Methods</h4>Our post hoc analysis of the Therapeutics for Inpatients with COVID-19 platform trial utilized proportional hazards models to assess relationships between Day (D) 0 lymphopenia (ALC < 0.9 cells/uL), D0 severe lymphopenia (ALC < 0.5 cells/uL) or lymphopenia trajectory between D0 and D5 with mortality and secondary infections, and with sustained recovery using Fine-Gray models. Logistic regression was used to assess relationships between clinical variables and D0 lymphopenia or lymphopenia trajectory.<h4>Results</h4>D0 lymphopenia (1426/2579) and seve"],"journal":["BMC infectious diseases"],"pubmed_title":["Blood absolute lymphocyte count and trajectory are important in understanding severe COVID-19."],"pmcid":["PMC11734232"],"funding_grant_id":["1OT2HL156812-01","OT2 HL156812"],"pubmed_authors":["Aberg JA","Lundgren J","Gardner EM","Vasudeva S","Goodman AL","Aggarwal NR","Paules CI","Vock DM","Shaw-Saliba K","North CM","Kumarasamy N","STRIVE Network and TICO Trial Study Group","Nordwall JA"],"additional_accession":[]},"is_claimable":false,"name":"Blood absolute lymphocyte count and trajectory are important in understanding severe COVID-19.","description":"<h4>Background</h4>Low blood absolute lymphocyte count (ALC) may predict severe COVID-19 outcomes. Knowledge gaps remain regarding the relationship of ALC trajectory with clinical outcomes and factors associated with lymphopenia.<h4>Methods</h4>Our post hoc analysis of the Therapeutics for Inpatients with COVID-19 platform trial utilized proportional hazards models to assess relationships between Day (D) 0 lymphopenia (ALC < 0.9 cells/uL), D0 severe lymphopenia (ALC < 0.5 cells/uL) or lymphopenia trajectory between D0 and D5 with mortality and secondary infections, and with sustained recovery using Fine-Gray models. Logistic regression was used to assess relationships between clinical variables and D0 lymphopenia or lymphopenia trajectory.<h4>Results</h4>D0 lymphopenia (1426/2579) and seve","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2026-05-02T14:31:31.673Z","creation":"2025-04-06T01:15:04.806Z"},"accession":"S-EPMC11734232","cross_references":{"pubmed":["39810077"],"doi":["10.1186/s12879-024-10428-7"]}}